Featured Research

from universities, journals, and other organizations

Greater surgeon experience increases likelihood of mitral valve repair vs replacement

Date:
April 30, 2014
Source:
American Association for Thoracic Surgery (AATS)
Summary:
Even today, significant variations – among surgeons and hospitals - still exist in the performance of mitral valve repair vs replacement for moderate to severe mitral regurgitation, shows a large-scale study. Significant associations were observed between the propensity for MV repair and both institutional and surgeon annual volume, although increasing surgeon volume appears to be the much stronger predictor.

A new study presenting data from 17 cardiac surgical centers in Virginia, representing 100 surgeons and 99% of cardiac operations performed in the state, demonstrates that, even today, significant variations -- among surgeons and hospitals -- still exist in the performance of mitral valve repair vs replacement for moderate to severe mitral regurgitation. Significant associations were observed between the propensity for MV repair and both institutional and surgeon annual volume, although increasing surgeon volume appears to be the much stronger predictor.

Damien J. LaPar, MD, MSc, of the Division of Thoracic and Cardiovascular Surgery at the University of Virginia (Charlottesville), is presenting the results of this research at the 94th AATS Annual Meeting in Toronto, ON, Canada on April 30, 2014.

When the mitral valve (MV) leaks, blood can flow backward or "regurgitate" into the upper heart chamber, leading to decreased blood flow to the rest of the body. To compensate, the heart may try to pump harder, and this can result in congestive heart failure. When regurgitation is severe, the standard of care treatment is MV surgery. Two options are available: mitral value repair or replacement.

Professional associations such as the American College of Cardiology and the American Heart Association recommend mitral valve surgery over medical management for severe mitral regurgitation. Yet, only 50% of patients meeting the ACC/AHA guidelines for surgical treatment undergo surgery. Furthermore, while MV repair is associated with superior perioperative outcomes and reduced mortality compared to replacement, it appears to be underutilized.

In this large, multi-institutional retrospective study from the Virginia Cardiac Surgery Quality Initiative, more than 4,000 patients were evaluated, and 60% underwent MV repair. Significant variations were seen in MV repair rates among hospitals (35-70% of MV procedures) and surgeons (0-90%).

The results suggest that what type of surgery a patient received depended in part on how experienced the surgeon was. After adjustment for baseline preoperative patient risk, when the propensity to perform an MV repair was plotted against surgeon volume, it became apparent that there was an "inflection point" of increased probability for mitral repair when the average annual surgeon volume (a surrogate for surgeon experience) exceeded approximately 20 surgeries a year. Surgeons who performed more than 20 MV surgeries a year were between 3 and 4 times more likely to perform a repair than replacement compared to those who operated less than 20 times a year.

Dr. LaPar suggests that the results may have important future implications on patient referral of care and quality measure assessment. "In the upcoming era of percutaneous MV repair technology, surgeon volume and expertise as a gatekeeper should dictate access to this technology and the decisions for approach to MV repair."


Story Source:

The above story is based on materials provided by American Association for Thoracic Surgery (AATS). Note: Materials may be edited for content and length.


Cite This Page:

American Association for Thoracic Surgery (AATS). "Greater surgeon experience increases likelihood of mitral valve repair vs replacement." ScienceDaily. ScienceDaily, 30 April 2014. <www.sciencedaily.com/releases/2014/04/140430082719.htm>.
American Association for Thoracic Surgery (AATS). (2014, April 30). Greater surgeon experience increases likelihood of mitral valve repair vs replacement. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/04/140430082719.htm
American Association for Thoracic Surgery (AATS). "Greater surgeon experience increases likelihood of mitral valve repair vs replacement." ScienceDaily. www.sciencedaily.com/releases/2014/04/140430082719.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins